Skip to main content

Table 3 Baseline demographics, classifications, and disease characteristics of all, non-responders, responders, super non-responders and super-responders

From: Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders

  

All patients

Non responders

Responders

P value

Super non responders

Super responders

P value

Age

 

34.3 (10.9)

36.5 (13.3)

32.7 (8.6)

0.56 (Mann–Whitney)

42 (13.2)

30.6 (8.7)

0.042 (Mann–Whitney)

Sex

Female

38 (82%)

16 (84%)

22 (82%)

 

7 (88%)

10 (91%)

 

Male

8 (18%)

3 (16%)

5 (18%)

1 (Fisher exact)

1 (12%)

1 (9%)

1 (Fisher exact)

Years with migraine

 

16.6 (11.2)

19.2 (13.3)

14.8 (9.4)

0.31 (Mann–Whitney)

28.2 (28)

15.8 (9.2)

0.047 (Mann–Whitney)

% migraine days per month

 

47.7 (18.4)

50.7 (22.0)

45.5 (15.4)

0.28 (Mann–Whitney)

51.2 (27.8)

51.2 (19.9)

0.93 (Mann–Whitney)

Classification

EM

27 (58%)

8 (42%)

19 (70%)

 

4 (50%)

6 (54%)

 

CM

19 (42%)

11 (58%)

8 (30%)

0.072 (Fisher exact)

4 (50%)

5 (46%)

1 (Fisher exact)

BMI

 

25.3 (5.3)

25.0 (6.0)

25.5 (4.8)

0.25 (Mann–Whitney)

24.3 (7.1)

24.3 (5.1)

(Mann–Whitney)

MIDAS

little

3 (7%)

3 (15%)

0

 

0

0

 

mild

3 (7%)

2 (10%)

1 (4%)

 

1 (12%)

0

 

moderate

8 (17%)

3 (15%)

5 (18%)

 

2 (25%)

3 (27%)

 

severe

32 (69%)

11 (60%)

21 (78%)

0.13 (Fisher exact)

5 (63%)

8 (73%)

0.77 (Fisher exact)

Aura (visual, sensory and speech)

 

28 (60%)

13 (68%)

15 (55%)

0.54 (Mann–Whitney)

4 (50%)

5 (45%)

1 (Mann–Whitney)